» Articles » PMID: 36439258

Acute Effects of Cardiac Contractility Modulation Stimulation in Conventional 2D and 3D Human Induced Pluripotent Stem Cell-derived Cardiomyocyte Models

Overview
Journal Front Physiol
Date 2022 Nov 28
PMID 36439258
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiac contractility modulation (CCM) is a medical device therapy whereby non-excitatory electrical stimulations are delivered to the myocardium during the absolute refractory period to enhance cardiac function. We previously evaluated the effects of the standard CCM pulse parameters in isolated rabbit ventricular cardiomyocytes and 2D human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) monolayers, on flexible substrate. In the present study, we sought to extend these results to human 3D microphysiological systems to develop a robust model to evaluate various clinical CCM pulse parameters . HiPSC-CMs were studied in conventional 2D monolayer format, on stiff substrate (i.e., glass), and as 3D human engineered cardiac tissues (ECTs). Cardiac contractile properties were evaluated by video (i.e., pixel) and force-based analysis. CCM pulses were assessed at varying electrical 'doses' using a commercial pulse generator. A robust CCM contractile response was observed for 3D ECTs. Under comparable conditions, conventional 2D monolayer hiPSC-CMs, on stiff substrate, displayed no contractile response. 3D ECTs displayed enhanced contractile properties including increased contraction amplitude (i.e., force), and accelerated contraction and relaxation slopes under standard acute CCM stimulation. Moreover, 3D ECTs displayed enhanced contractility in a CCM pulse parameter-dependent manner by adjustment of CCM pulse delay, duration, amplitude, and number relative to baseline. The observed acute effects subsided when the CCM stimulation was stopped and gradually returned to baseline. These data represent the first study of CCM in 3D hiPSC-CM models and provide a nonclinical tool to assess various CCM device signals in 3D human cardiac tissues prior to animal studies. Moreover, this work provides a foundation to evaluate the effects of additional cardiac medical devices in 3D ECTs.

Citing Articles

Acute Biomechanical Effects of Cardiac Contractility Modulation in Living Myocardial Slices from End-Stage Heart Failure Patients.

Bierhuizen M, Amesz J, Langmuur S, Lam B, Knops P, Veen K Bioengineering (Basel). 2025; 12(2).

PMID: 40001693 PMC: 11851609. DOI: 10.3390/bioengineering12020174.


Pulsed electric field performance calculator tool based on an human cardiac model.

Casciola M, Kaboudian A, Feaster T, Narkar A, Blinova K Front Physiol. 2024; 15:1395923.

PMID: 38911328 PMC: 11190366. DOI: 10.3389/fphys.2024.1395923.


Optical Mapping of Cardiomyocytes in Monolayer Derived from Induced Pluripotent Stem Cells.

Djemai M, Cupelli M, Boutjdir M, Chahine M Cells. 2023; 12(17).

PMID: 37681899 PMC: 10487143. DOI: 10.3390/cells12172168.


Commentary: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models.

Bierhuizen M, Amesz J, de Groot N, Taverne Y Front Physiol. 2023; 14:1130674.

PMID: 36846319 PMC: 9948438. DOI: 10.3389/fphys.2023.1130674.


Human assay for irreversible electroporation cardiac ablation.

Casciola M, Feaster T, Caiola M, Keck D, Blinova K Front Physiol. 2023; 13:1064168.

PMID: 36699682 PMC: 9869257. DOI: 10.3389/fphys.2022.1064168.

References
1.
Qu Y, Feric N, Pallotta I, Singh R, Sobbi R, Vargas H . Inotropic assessment in engineered 3D cardiac tissues using human induced pluripotent stem cell-derived cardiomyocytes in the Biowire II platform. J Pharmacol Toxicol Methods. 2020; 105:106886. DOI: 10.1016/j.vascn.2020.106886. View

2.
Blinova K, Schocken D, Patel D, Daluwatte C, Vicente J, Wu J . Clinical Trial in a Dish: Personalized Stem Cell-Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT-Prolonging Drugs. Clin Transl Sci. 2019; 12(6):687-697. PMC: 6853144. DOI: 10.1111/cts.12674. View

3.
Winter J, Brack K, Coote J, Ng G . Cardiac contractility modulation increases action potential duration dispersion and decreases ventricular fibrillation threshold via β1-adrenoceptor activation in the crystalloid perfused normal rabbit heart. Int J Cardiol. 2014; 172(1):144-54. PMC: 3978661. DOI: 10.1016/j.ijcard.2013.12.184. View

4.
Bartolucci C, Passini E, Hyttinen J, Paci M, Severi S . Simulation of the Effects of Extracellular Calcium Changes Leads to a Novel Computational Model of Human Ventricular Action Potential With a Revised Calcium Handling. Front Physiol. 2020; 11:314. PMC: 7174690. DOI: 10.3389/fphys.2020.00314. View

5.
Burnett S, Blanchette A, Chiu W, Rusyn I . Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors. Chem Res Toxicol. 2021; 34(9):2110-2124. PMC: 8762671. DOI: 10.1021/acs.chemrestox.1c00203. View